Royce Bargas, DO
Clinical Cardiac Electrophysiology · Edmond, OKNPI 1013063635
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 47.6% of the total. Reporting peaked in 2020 at $811 and has fallen 67.7% since, to $262 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in OK, where the typical reported total is $22,745.
Across 59 payments — averaging $40.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boston Scientific$181
- E.r. Squibb & Sons, L.L.C.$130
- Biosense Webster, Inc.$122
- Novartis$120
- Regeneron Healthcare Solutions, Inc.$115
- plus $578 from 16 others
What the payments were for
- Consulting fees$93639%
- Food & beverage$1,42060%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $1,133 |
| Boston Scientific | 9 | $181 |
| E.r. Squibb & Sons, L.L.C. | 1 | $130 |
| Biosense Webster, Inc. | 3 | $122 |
| Novartis | 7 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $84 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Cleerly, Inc. | 1 | $60 |
| Medtronic | 3 | $58 |
| Merck | 3 | $57 |
| Boehringer Ingelheim | 3 | $50 |
| Novo Nordisk | 2 | $34 |
| Corcept Therapeutics | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Avion Pharmaceuticals | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Preventice Services, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,378 in reported general payments places this provider in the 10th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $113,823 |
| EntrestoSacubitril/Valsartan | 44 | $42,073 |
| XareltoRivaroxaban | 26 | $21,549 |
| OzempicSemaglutide | 11 | $9,911 |
| Praluent PenAlirocumab | 12 | $5,790 |
| ProgesteroneProgesterone, Micronized | 88 | $2,930 |
| Rosuvastatin Calcium | 115 | $2,222 |
| Flecainide Acetate | 22 | $1,418 |
| Ezetimibe | 89 | $1,379 |
| Dofetilide | 19 | $1,258 |
| Metoprolol Succinate | 66 | $1,230 |
| Amiodarone Hcl | 25 | $1,183 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $1,067 |
| Losartan Potassium | 92 | $1,001 |
| Amlodipine Besylate | 37 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $120 | $42,07344 claims |
| Novo NordiskOzempic | $34 | $9,91111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Edmond
- Warren JackmanOklahoma City$2.3M
- Sunny PoOklahoma City$260K
- John SummersOklahoma City$135K
- Sean HalleranOklahoma City$105K
- David SandlerTulsa$86K
- Ian ParkerOklahoma City$74K
- Craig CameronTulsa$52K
- Vikram KatariTulsa$34K
- Paul GarabelliOklahoma City$33K
- Venkatesh RaviTulsa$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.